On November 20, Recursion Pharmaceuticals, Inc. fell 5.51% in Regular Trading, trading at $2.575 per share, with turnover of $22.0097 million.
The move followed continued market digestion of the company’s previously disclosed alignment with the FDA on the registrational Phase 3 trial design for REC-4881 in familial adenomatous polyposis, as investors remained focused on execution timing rather than the headline regulatory update alone.
Company disclosures indicated the Phase 3 study is expected to enroll about 200 adult patients who have undergone colectomy or proctocolectomy, evaluate a 4 mg dose, and is on track to begin in the second half of 2027. Secondary endpoints include modified Spigelman stage progression and polyp burden. Earlier updated TUPELO data had shown deep and durable reductions in polyp burden, helping support advancement toward a registrational pathway.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments